Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Up 5.18%
As of Thursday, October 29, Palvella Therapeutics, Inc.’s PVLA share price has surged by 5.18%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Commentary & Analysis
Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Up 6.98%
As of Wednesday, October 28, Palvella Therapeutics, Inc.’s PVLA share price has surged by 6.98%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Down 5.22%
As of Friday, October 16, Palvella Therapeutics, Inc.’s PVLA share price has dipped by 5.22%, which has investors questioning if this is right time to buy.Michael Rose
Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Down 5.45%
As of Wednesday, October 14, Palvella Therapeutics, Inc.’s PVLA share price has dipped by 5.45%, which has investors questioning if this is right time to buy.Michael Rose
Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Down 5.65%
As of Wednesday, September 23, Palvella Therapeutics, Inc.’s PVLA share price has dipped by 5.65%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | PVLA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,338.2 | $227.3 | 57% |
|
| Shares Out (Mil) | 14.4 | 53.4 | 26% |
|
| Institutional Ownership | 92.2% | 92.9% | 61% |
|
| Float (Mil) | 10.7 | 41.4 | 20% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 261 | 468 | 49% |
|
| Price Change (52-week) |
111.2% | 47.4% | 96% |
|
| Growth | PVLA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 13 | 13 | 11 | |
| Current EPS | ($1.732) | ($6.387) | ($7.906) | |
| Month Ago EPS | ($1.743) | ($6.422) | ($7.498) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 3 | |
| Three Months Ago EPS | ($1.735) | ($6.371) | ($7.498) | |
| Year/Year Chg | 13.7% | 72.2% | 68.9% | |
| Financials | PVLA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($62) | ($44) | 15% |
|
| EPS (TTM) | ($4.898) | ($1.600) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($37) | ($34) | 11% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $22 | $4 | 33% |
|
| Enterprise Value (Q1) (Mil) | $1,983 | $174 | 49% |
|
| Valuation | PVLA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 10.78 | 2.14 | 92% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PVLA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.5% | na |
|
| Net Margin | na | (69.8%) | na |
|
| ROA | (37.7%) | (47.1%) | 14% |
|
| ROE | (46.6%) | (52.0%) | 16% |
|
| Liabilities to Assets | 14.5% | 29.7% | 9% |
|
| F-Score | 4 | 2 | 33% |
|
Palvella Therapeutics, Inc. did not pass any screens on 11/4/2026.
